DSM-Firmenich Past Earnings Performance
Past criteria checks 0/6
DSM-Firmenich's earnings have been declining at an average annual rate of -33.5%, while the Chemicals industry saw earnings growing at 13.9% annually. Revenues have been growing at an average rate of 1.5% per year.
Key information
-33.5%
Earnings growth rate
-31.8%
EPS growth rate
Chemicals Industry Growth | 12.9% |
Revenue growth rate | 1.5% |
Return on equity | -2.8% |
Net Margin | -6.2% |
Next Earnings Update | 30 Jul 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How DSM-Firmenich makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 10,627 | -658 | 2,535 | 652 |
30 Sep 23 | 9,686 | -456 | 1,772 | 295 |
30 Jun 23 | 8,745 | -254 | 1,772 | 295 |
31 Mar 23 | 8,568 | 100 | 1,772 | 295 |
31 Dec 22 | 8,390 | 454 | 1,772 | 295 |
30 Sep 22 | 9,582 | 837 | 895 | 162 |
30 Jun 22 | 7,867 | 823 | 1,649 | 274 |
31 Mar 22 | 7,568 | 822 | 1,649 | 274 |
31 Dec 21 | 7,269 | 820 | 1,649 | 274 |
30 Sep 21 | 7,955 | 660 | 2,517 | 560 |
30 Jun 21 | 7,558 | 493 | 1,622 | 398 |
31 Mar 21 | 7,572 | 423 | 1,622 | 398 |
31 Dec 20 | 8,106 | 448 | 1,622 | 398 |
30 Sep 20 | 7,960 | 510 | 1,639 | 295 |
30 Jun 20 | 8,034 | 557 | 1,639 | 295 |
31 Mar 20 | 9,011 | 722 | 1,795 | 349 |
31 Dec 19 | 7,998 | 675 | 1,639 | 295 |
30 Sep 19 | 8,272 | 820 | 1,839 | 348 |
30 Jun 19 | 8,502 | 794 | 1,839 | 348 |
31 Mar 19 | 9,124 | 934 | 1,839 | 348 |
31 Dec 18 | 9,267 | 1,069 | 1,839 | 348 |
30 Sep 18 | 9,235 | 984 | 1,753 | 334 |
30 Jun 18 | 9,106 | 2,082 | 1,753 | 334 |
31 Mar 18 | 8,908 | 1,942 | 1,753 | 334 |
31 Dec 17 | 8,632 | 1,761 | 1,753 | 334 |
30 Sep 17 | 8,471 | 1,676 | 1,694 | 309 |
30 Jun 17 | 8,333 | 738 | 1,694 | 309 |
31 Mar 17 | 8,166 | 711 | 1,694 | 309 |
31 Dec 16 | 7,920 | 645 | 1,694 | 309 |
30 Sep 16 | 7,831 | 588 | 1,605 | 332 |
30 Jun 16 | 7,778 | 274 | 1,605 | 332 |
31 Mar 16 | 7,749 | 214 | 1,605 | 332 |
31 Dec 15 | 7,722 | 174 | 1,605 | 332 |
30 Sep 15 | 7,607 | 66 | 1,382 | 304 |
30 Jun 15 | 7,456 | 114 | 1,382 | 304 |
31 Mar 15 | 7,245 | 115 | 1,382 | 304 |
31 Dec 14 | 7,051 | 123 | 1,382 | 304 |
30 Sep 14 | 7,415 | 112 | 1,430 | 340 |
30 Jun 14 | 7,834 | 138 | 1,430 | 340 |
31 Mar 14 | 8,362 | 182 | 1,430 | 340 |
31 Dec 13 | 8,858 | 252 | 1,430 | 340 |
30 Sep 13 | 8,409 | 363 | 1,396 | 372 |
30 Jun 13 | 8,500 | 335 | 1,396 | 372 |
Quality Earnings: KDSK.F is currently unprofitable.
Growing Profit Margin: KDSK.F is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: KDSK.F is unprofitable, and losses have increased over the past 5 years at a rate of 33.5% per year.
Accelerating Growth: Unable to compare KDSK.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: KDSK.F is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (-11.9%).
Return on Equity
High ROE: KDSK.F has a negative Return on Equity (-2.76%), as it is currently unprofitable.